Cocrystal Pharma (COCP) risk factors
Item 1A of every Cocrystal Pharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors51 risks2 new8 reworded
Clinical delays plague our Influenza A program following a failed Phase 2a trial and a major CRO dispute over $6,309,000. Going concern doubts intensify as accumulated losses reach $342.2 million and additional warrant issuances create shareholder dilution.
Filed Mar 31, 2026 - FY2024 10-K risk factors49 risks
Cocrystal Pharma faces substantial going concern doubt with an accumulated deficit of $333,418,000 as of December 31, 2024. The company relies entirely on early-stage preclinical and clinical antiviral drug candidates without any commercial product sales. Operations depend heavily on third-party partners, contractors, and intellectual property protection.
Filed Mar 31, 2025